Opus Genetics Files Proxy Materials
Ticker: IRD · Form: DEFA14A · Filed: Apr 10, 2025 · CIK: 1228627
Sentiment: neutral
Topics: proxy-filing, amendment, corporate-actions
TL;DR
Opus Genetics dropped more proxy docs, no fee needed.
AI Summary
Opus Genetics, Inc. filed a Definitive Additional Materials proxy statement on April 10, 2025. This filing is an amendment to previous proxy materials and does not require a filing fee. The company was formerly known as Ocuphire Pharma, Inc., Rexahn Pharmaceuticals, Inc., and Corporate Road Show Dot Com Inc.
Why It Matters
This filing provides additional information to shareholders regarding company matters, which is crucial for informed voting decisions at shareholder meetings.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement amendment and does not contain new financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Former company name
- Rexahn Pharmaceuticals, Inc. (company) — Former company name
- Corporate Road Show Dot Com Inc (company) — Former company name
- 20250410 (date) — Filing date
FAQ
What is the purpose of this DEFA14A filing?
This filing is for Definitive Additional Materials, indicating it supplements previously filed proxy statements and is not a preliminary proxy statement.
Does Opus Genetics require a filing fee for this document?
No, the filing explicitly states 'No fee required.'
What were Opus Genetics' previous names?
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc., Rexahn Pharmaceuticals, Inc., and Corporate Road Show Dot Com Inc.
When was the company's name last changed?
The most recent name change was from Ocuphire Pharma, Inc. on November 9, 2020.
What is the standard industrial classification for Opus Genetics?
The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 10, 2025 regarding Opus Genetics, Inc. (IRD).